---
title: "Aditxt, Inc. 1Q 2026: Revenue $12.16K, Net income ($15.95M), EPS ($790.49) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287117452.md"
description: "Aditxt, Inc. reported Q1 2026 results with revenue of $12.16K, a net loss of $15.95M, and diluted EPS of ($790.49), reflecting significant growth from the Ignite acquisition but increased operating costs. Revenue rose 1094.4% year-over-year. The company completed preclinical studies and expanded its laboratory capacity, while also engaging in partnerships to support future clinical trials."
datetime: "2026-05-20T20:41:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287117452.md)
  - [en](https://longbridge.com/en/news/287117452.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287117452.md)
---

# Aditxt, Inc. 1Q 2026: Revenue $12.16K, Net income ($15.95M), EPS ($790.49) — 10-Q Summary

Aditxt, Inc. reported first-quarter 2026 results showing revenue of $12.16K, a wider net loss of ($15.95M) and diluted EPS of ($790.49) versus the prior-year quarter, reflecting growth in sales tied to the Ignite acquisition alongside increased operating costs related to development and integration activities.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$12.16K

$1.02K

1094.4%

Net income²

($15.95M)

($5.71M)

(179.3%)

Diluted EPS³

($790.49)

($198072.98)

99.6%

_¹ Reported as “Sales”. ² Reported as “Net Loss Attributable To Aditxt, Inc. & Subsidiaries”. ³ Reported as “loss per share, basic and diluted”._

**Business Highlights**

-   Revenue growth to $12.2K in Q1 2026 from $1.0K in Q1 2025 was driven by the Ignite acquisition.
-   Completed ADI-100 preclinical studies and GMP manufacturing of clinical‑grade drug substance in preparation for IND submissions.
-   Pearsanta acquisition added Mitomic® and Adductomics assets; development continues on MPT™ and MET™ blood-based tests and build-out of CLIA laboratory capacity.
-   Clinical and partnership progress includes CRO engagement in Germany and collaboration with Mayo Clinic to support IND and planned SPS trial enrollment in 2026.

Original SEC Filing: Aditxt, Inc. \[ ADTX \] - 10-Q - May. 20, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ADTX.US](https://longbridge.com/en/quote/ADTX.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)
- [Korro Bio To Advance KRRO-111 As Potential Treatment For AATD](https://longbridge.com/en/news/287089978.md)
- [08:00 ETAvance Clinical Receives Frost & Sullivan's 2026 Global Company of the Year Recognition for Excellence in Biotech CRO Leadership](https://longbridge.com/en/news/286094661.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)